White label ELPA - ClinicalTrials.eu

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Recruiting

3 1 1 1
Investigated Drugs:
- Topotecan Hydrochloride
+5
Efficacy of high- and low-dose psilocybin in preventing relapse in adults with severe alcohol use disorder and depressive symptoms after detoxification

Recruiting

3 1 1
Investigated Diseases:
- Depression
Investigated Drugs:
- Psilocybine
Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2

Recruiting

3 1
Investigated Drugs:
- Alks 2680
+4
Safety Study of NB-4746 with Riluzole and Placebo in Adults with Amyotrophic Lateral Sclerosis (ALS)

Recruiting

1 1 1
Investigated Diseases:
- Amyotrophic lateral sclerosis
Investigated Drugs:
- Riluzole
Randomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Recruiting

4 1 1 1
Investigated Drugs:
- Aflibercept
Phase 1/2 Study of CR-001 Safety and Dose Finding in Adults with Locally Advanced or Metastatic Solid Tumors

Recruiting

2 1 1
Investigated Diseases:
Randomized Study of Tolebrutinib Versus Rituximab in Adults with Multiple Sclerosis

Recruiting

3 1 1 1
Investigated Diseases:
- Multiple sclerosis
Investigated Drugs:
- Tolebrutinib
- Rituximab
Phase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1

Recruiting

3 1
Investigated Drugs:
- Alks 2680
+6
Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Recruiting

3 1 1
Investigated Drugs:
- Bendamustine Hydrochloride
- Rituximab
A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

Recruiting

3 1 1 1
Investigated Diseases:
- Factor VIII deficiency
Investigated Drugs:
- Ro7589655
- Simoctocog Alfa
+3

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies